SWOG clinical trial number
CTSU/GU002
Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy with or Without Adjuvant Docetaxel
Closed
Abbreviated Title
Adj RT and ADT following radical prostatectomy w/ or w/o Adj Docetaxel, Phase II-III
Status Notes
Closed to accrual as of 9/6/2022.
Activated
12/30/2016
Closed
09/06/2022
Participants
CTSU
Research committees
Genitourinary Cancer
Treatment
Docetaxel
Leuprolide Acetate
Degarelix
Other Clinical Trials
SWOG Clinical Trial Number
S2427
Single Arm Phase II Study of Bladder Preservation with Immunoradiotherapy after a Clinically Meaningful Response to Neoadjuvant Therapy in Patients with Muscle Invasive Bladder Cancer (BRIGHT)
Research Committee(s)
Genitourinary Cancer
Activated
09/04/2025
Accrual
1%
Open
Phase
SWOG Clinical Trial Number
CCTG-PR26
A Randomized Phase III Clinical Trial for the Addition of Docetaxel to Androgen Receptor Pathway Inhibitors in Patients with Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response (TRIPLE-SWITCH)
Research Committee(s)
Genitourinary Cancer
Activated
01/30/2025
Open
Phase
SWOG Clinical Trial Number
S2312
A Phase III Study of Cabazitaxel with or without Carboplatin in Patients with metastatic castrate-resistant prostate cancer (mCRPC), Stratified by Aggressive Variant Signature
Research Committee(s)
Genitourinary Cancer
Activated
09/03/2024
Accrual
7%
Open
Phase